MORC3 and clinically amyopathic dermatomyositis: Patients with CDM had higher levels of negative myositis-specific autoantibodies (20.9% vs. 7.6%, P=0.001) and anti-NXP2 antibodies (7.7% vs. 1.5%, P=0.029) than those with CADM.